Eli Lilly and Company announced it will acquire Centessa Pharmaceuticals in a transaction valued at up to $7.8 billion, marking a significant expansion into the sleep disorder treatment market.

Centessa Pharmaceuticals specializes in developing experimental medications for sleep disorders, representing a strategic addition to Lilly's pharmaceutical portfolio. The acquisition reflects growing industry interest in sleep medicine as a therapeutic area with substantial market potential.

The deal structure allows for payments up to the $7.8 billion maximum, though specific terms regarding upfront payments versus milestone-based compensation were not detailed in the initial announcements. This acquisition represents one of the larger pharmaceutical transactions in the sleep disorder space.

For Lilly, the acquisition expands its therapeutic reach beyond its current focus areas, which include diabetes treatments like its popular GLP-1 medications. The company has been actively pursuing strategic acquisitions to diversify its drug pipeline and capture growth in emerging therapeutic markets.

The transaction is subject to customary closing conditions and regulatory approvals. Upon completion, Centessa's sleep disorder drug candidates will join Lilly's development pipeline, potentially accelerating their path to market through Lilly's established commercialization capabilities.